Abstract 327TiP
Background
Management of platinum resistant ovarian cancer has always been challenging for oncologists. Best option in this setting is single agent chemotherapy with bevacizumab. However, due to various contraindications and financial constraints, many of them do not receive bevacizumab. Due to high expression of folate receptor alpha in high grade epithelial ovarian cancers pemetrexed could be a potential treatment option. To our knowledge there are only 2 phase II trials across the globe showing the effectiveness of pemetrexed in platinum resistant/refractory ovarian cancer and till date there is no prospective data in Indian patients with platinum resistant/refractory ovarian cancer.
Trial design
The study is a single centre, investigator-initiated, single arm phase II clinical trial designed using Simon two stage optimal design. Eligible patients are adults (age ≥18 years), with histologically confirmed high grade epithelial ovarian or primary peritoneal cancer, who have relapsed within 6 months of platinum-based chemotherapy, who are bevacizumab ineligible, with ECOG performance status of 0-2, adequate organ function, with either measurable disease with at least one target lesion for response evaluation as per RECIST 1.1 criteria or non-measurable disease with CA-125 level ≥2 times ULN measured at least 2 weeks before enrolment. Estimated sample size is 63. At least 2 out of 22 responses in stage I are expected in order to proceed to stage II and further recruitment of the patients. Baseline contrast enhanced CT scan of chest, abdomen and pelvis along with CA-125 level will be recorded. Eligible patients will receive Pemetrexed at dose of 500 mg/m2 every 21 days. Response assessment will be done after 3 cycles of chemotherapy (RECIST 1.1 will be used for measurable disease and GCIG criteria using CA-125 level will be used for non-measurable disease) and subsequent responses will be assessed every 12-16 weeks. Treatment will continue until progression, intolerable toxicity or death. Primary objective is Objective Response Rate (ORR). Secondary objectives are Progression Free survival (PFS), Overall Survival (OS), Clinical Benefit Rate (CBR), Toxicity profile and Quality of Life (QoL).
Clinical trial identification
CTRI/2022/08/044939.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract